Teva and MAbxience Expand Strategic Partnership to Include an Additional Oncology Biosimilar Candidate
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Teva Pharmaceutical's US Affiliate Launches Octreotide Acetate for Injectable Suspension
Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 A.m. ET on November 6, 2024
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Amazon to Provide Opioid Overdose Drug in Workplace
Harris Vs. Trump: 2024 Election Poll Shows Good, Bad News For Each Candidate
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Revenues Are Not Doing Enough For Some Investors
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
Teva Pharmaceutical's Movement Disorder Drug Shows Sustained Improvement in Extension Study
Reported Saturday, Teva Unveils Data on UZEDY Injection Switching Strategy for Schizophrenia Treatment at ECNP
Reported Saturday, Teva's New Schizophrenia Treatment TEV-749 Meets Key Endpoints in Phase 3 Study
Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data From Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed With Schizophrenia
Medincell's Partner Teva Provided Treatment Insights Into Switching to UZEDY From Perseris
Express News | Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients With Debilitating Movement Disorder Tardive Dyskinesia